VTGN Stock Update: Notable Pre-Market Surge, Analyst Favor, and Future Outlook

Vistagen Therapeutics Inc (VTGN) has experienced a 7.67% increase in pre-market trading, reaching $4.77.

Stock Performance

Stock Performance

With a short-term technical score of 10, VTGN's recent trading shows less bullish activity compared to 90% of other stocks in the market.

Technical Score

Technical Score

In the Biotechnology industry, VTGN holds a rank higher than 21% of stocks, although the industry itself ranks 134 out of 146.

Industry Ranking

Industry Ranking

Over the past month, VTGN's stock has risen by 30.68%, closing at $2.89 on November 9. The stock's lowest point during this period was $2.57, and the highest was $4.49.

Month-over-Month Growth

Month-over-Month Growth

The average analyst recommendation for VTGN is Strong Buy, with an average price target of $12.00.

Analyst Recommendation

Analyst Recommendation

With a Long-Term Technical rank of 53, VTGN is positioned in the upper half of stocks based on trading over the last 200 days, surpassing 47% of the market. In the Biotechnology industry, VTGN outperforms 118% of stocks.

Long-Term Technical Rank

Long-Term Technical Rank

VTGN is scheduled to release earnings on February 7, 2024. The company has reported earnings per share (EPS) of $-4.81 over the last 12 months, and there is no set dividend date available at present.

Upcoming Events

Upcoming Events